Literature DB >> 2725334

Progestogen addition during oestrogen replacement therapy--effects on vasomotor symptoms and mood.

J Holst1, T Bäckström, S Hammarbäck, B von Schoultz.   

Abstract

Vasomotor symptoms and mood changes were followed in 2 groups of post-menopausal women receiving cyclic replacement therapy with 3 mg/day of percutaneous oestradiol-17 beta alone or in sequential combination (days 11-21) with lynestrenol 5 mg/day. During 6 mth of therapy, daily symptom ratings were performed using a visual analogue scale technique. Serum levels of oestradiol were similar in both groups but sequential oestrogen/progestogen treatment was more efficient in suppressing vasomotor symptoms and serum gonadotropins. However, all negative mood symptoms were also more pronounced in this group. Progestogen addition may enhance the therapeutic effect on hot flushes and sweats but, at least in individual women cause unfavourable effects on mental status, mood and well-being.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2725334     DOI: 10.1016/0378-5122(89)90116-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

Review 1.  Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease.

Authors:  Michel Cyr; Frederic Calon; Marc Morissette; Thérèse Di Paolo
Journal:  J Psychiatry Neurosci       Date:  2002-01       Impact factor: 6.186

2.  Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone.

Authors:  Lotta Andréen; Inger Sundström-Poromaa; Marie Bixo; Sigrid Nyberg; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2006-05-25       Impact factor: 4.530

3.  Effect of medroxyprogesterone on depressive symptoms in depressed and nondepressed perimenopausal and postmenopausal women after discontinuation of transdermal estradiol therapy.

Authors:  Maria Pia Rogines-Velo; Amy E Heberle; Hadine Joffe
Journal:  Menopause       Date:  2012-04       Impact factor: 2.953

Review 4.  Ovarian steroids and serotonin neural function.

Authors:  C L Bethea; M Pecins-Thompson; W E Schutzer; C Gundlah; Z N Lu
Journal:  Mol Neurobiol       Date:  1998-10       Impact factor: 5.590

Review 5.  Breast cancer prevention through modulation of endogenous hormones.

Authors:  D V Spicer; M C Pike
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.